Centers | ||
|
|
|
Therapeutic Accelerator Program (TAP) | VMCC, University of Michigan | Edinburgh Drug Discovery |
Test |
The VMCC is an on-campus core facility for the design and synthesis of drug-like molecules and diagnostic probes used in biomedical investigations. Our Mission: To assist biomedical researchers in translating novel therapeutic hypotheses into... |
Based within the world-leading University of Edinburgh Medical School, Edinburgh Drug Discovery has a track record in successfully translating drug discovery projects from target identification through to clinical evaluation. Key areas of... |
Partnerships |
Events |
Jobs |
Johns Hopkins BSi Licenses GCPII Assets from EisaiJohns Hopkins Brain Science Institute ("BSi") has taken a non-exclusive license from Eisai to develop new compounds related to Glutamate Carboxypeptidase II (GCP-II) technology. The new compounds developed under this license will be targeted... View all Sanofi and Stanford's Bio-X to Collaborate on Early Stage ResearchSanofi and Stanford University's Bio-X have entered into a multi-year collaboration that support interdisciplinary collaborative research to be conducted at Stanford. A joint steering committee comprising of representatives from Stanford and... View all Eisiai Partners with Johns Hopkins Brain Science InstituteEisiai Partners with Johns Hopkins Brain Science Institute ("BSi") an institute which is part of Johns Hopkins University to develop new drugs for neurological diseases. Under this joint collaboration, BSi will provide validated targets to Eisai... View all |
No EVENTS for listing |
No Job Posts |
